Market Overview

Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

Johnson & Johnson (NYSE: JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant.

On Thursday, Credit Suisse reinstated coverage of Johnson & Johnson stock with an Outperform rating and $148 price target. According to Divan, Johnson & Johnson has several key growth drivers ahead.


“Based on channel checks and detailed modeling we have done across various therapeutic areas, we see opportunities for significant upside from assets such as Xarelto, Darzalex and Imbruvica,” Divan wrote.

Related Link: Attention To Details: Neos' ADHD Portfolio

He noted that these growth drivers are not necessarily a result of the Actelion buyout. In fact, Divan said that at $29.1 billion, Johnson & Johnson likely overpaid for Actelion. Still, the deal certainly adds another long-term growth avenue for Johnson & Johnson.

In the near term, Johnson & Johnson has two potentially bullish catalysts ahead.

First, the company is expected to release COMPASS data for Xarelto at the European Society of Cardiology conference on August 29. Shortly thereafter, Johnson & Johnson has the PDUFA date for sirukumab in mod-sensitive rheumatoid arthritis on Sept. 22.

In addition, investors should look for the addition of more Remicade biosimilars in the second half of 2017, Divan said.

Over the long term, Divan sees the pharma business as the major growth driver. Credit Suisse estimates 5.8 percent compound annual growth from the pharma business through 2021 compared to just 3.7 percent annual growth for the medical devices business and 3.1 percent annual growth from the consumer business.

Credit Suisse’s $148 price target is based on 18.5x the company’s 2018 EPS forecast of $7.79.

Image Credit: By Raysonho @ Open Grid Scheduler / Grid Engine - Own work, CC0, via Wikimedia Commons

Latest Ratings for JNJ

Oct 2020Cantor FitzgeraldMaintainsOverweight
Oct 2020Credit SuisseMaintainsOutperform
Jul 2020Independent ResearchUpgradesHoldBuy

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas M&A Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

TUPDA DavidsonMaintains46.0
ANTMSVB LeerinkMaintains370.0
CCXISVB LeerinkMaintains84.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at